8月5日，康方生物盘中上涨3.04%，报96.7港元，成交额3.92亿港元。消息面上，创新药板块集体走强，同行业信达生物涨5.02%、康诺亚-B涨3.88%、百济神州涨3.25%。
近期多重利好共振推动板块上行：公司此前公布依沃西全球Ⅲ期HARMONi研究OS数据更新，西方患者总生存风险比改善至0.76，跨人种疗效一致性获验证；7月24日公司向167名承授人授出360.35万份购股权，行使价99.50港元，体现管理层对中长期发展信心。此外，下半年WCLC、ESMO等学术会议密集召开，核心管线数据披露预期持续催化板块情绪。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.